ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics (Nasdaq: ADMA) will report its fourth quarter and full year 2025 financial results on February 25, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) will report its fourth quarter and full year 2025 financial results on February 25, 2026 after market close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the company investor website.
Details
News Market Reaction – ADMA
On Feb 18, the day this news came out, ADMA closed 0.25% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Earnings release date
- February 25, 2026
- Fourth quarter and full year 2025 financial results
- Conference call time
- 4:30 p.m. ET
- Same day as 4Q and FY2025 earnings release
Historical Context
-
Preliminary FY2025 revenue and raised multi‑year guidance with business update.
-
Announcement of J.P. Morgan Healthcare Conference podium presentation and webcast.
-
3Q 2025 beat with revenue growth, net income, EBITDA expansion and guidance raise.
-
Scheduling of 3Q 2025 earnings release and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.